Synopsis:
Syschem (India) Limited, a Pharma Stock, reports 24% YoY revenue growth and a 1,185% YoY net profit surge in Q1 FY26 results.
This penny stock, engaged in manufacturing bulk drugs, APIs, intermediates, and specialty chemicals, and engaged in contract manufacturing within the pharmaceutical industry, jumped 7 percent after the company reported June quarterly results with a 1,185 percent YoY increase in net profit.
With a market capitalization of Rs. 200.16 crores, the share of Syschem (India) Limited has reached an intraday high of Rs. 47 per equity share, rising nearly 6.77 percent from its previous day’s close price of Rs. 44.02. Since then, the stock has retreated and is currently trading at Rs. 46 per equity share.
Q1 FY26 Result Walkthrough
Coming into the quarterly results of Syschem (India) Limited, the company’s consolidated revenue from operations increased by 24.09 percent YOY, from Rs. 102.15 crore in Q1 FY25 to Rs. 126.76 crore in Q1 FY26, and decreased by 8.64 percent QoQ from Rs. 138.75 crore in Q4 FY25.
In Q1 FY26, Syschem (India) Limited’s consolidated net profit increased by 1,184.62 percent YOY, reaching Rs. 1.67 crore compared to Rs. 0.13 crore during the same period last year. As compared to Q4 FY25, the net profit has increased by 263.04 percent, from Rs. 0.46 crore. The basic earnings per share increased by 1,166.67 percent and stood at Rs. 0.38 as against Rs. 0.03 recorded in the same quarter in the previous year, 2025.
Financial Highlights: Syschem (India) Limited’s revenue has increased from Rs. 199 crore in FY24 to Rs. 332 crore in FY25, which is a growth of 66.83 percent. The net profit has decreased by 84.67 percent, from Rs. 3 crore in FY24 to Rs. 0.46 crore in FY25.
Syschem (India) Limited’s revenue has grown at a CAGR of 77.87 percent over the last three years. In terms of return ratios, the company’s ROCE and ROE stand at 1.45 percent and 0.62 percent, respectively. Syschem (India) Limited has an earnings per share (EPS) of Rs. 0.45, and it’s a debt-free company.
Company Overview
Syschem (India) Limited was founded in 1993 and is a publicly listed Indian company specializing in the manufacturing of bulk drugs, active pharmaceutical ingredients (APIs), intermediates, specialty chemicals, and contract manufacturing.
The company operates its manufacturing facility in Kalka, Haryana. Syschem (India) specializes in the production of key antibiotics such as Amoxycillin Trihydrate, Ampicillin Trihydrate, Cloxacillin Sodium, Dicloxacillin Sodium, Cephalexin, Cefixime, and Cefadroxil.
The company also manufactures specialty solvents like DMF and Acetonitrile, serving both domestic and international markets with a focus on quality, compliance, and reliable chemical solutions.
Syschem (India) Limited operates across 12 Indian states and serves over seven international markets, establishing itself as a strong global player. Its products are exported to regions including Latin America, Africa, Thailand, Sri Lanka, Nepal, Indonesia, Germany, Bangladesh, and the MENA region, reflecting the company’s growing international presence and commitment to high-quality pharmaceutical and chemical solutions.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Pharma stock jumps 7% after company’s net profit increases by 1,185% YoY appeared first on Trade Brains.